A Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

  • STATUS
    Not Recruiting
  • days left to enroll
    61
  • participants needed
    24
  • sponsor
    Biogen
Updated on 3 April 2020
Investigator
US Biogen Clinical Trial Center
Primary Contact
Research Site (208.6 mi away) Contact
+6 other location
ct scan
dopamine
dopamine agonists
levodopa
anticholinergic agents
SPECT Scan
dopamine transporter
amantadine
parkinsonism
hoehn and yahr scale

Summary

The primary objective of this study is to evaluate the safety and tolerability of a range of single and 13 repeated doses of BIIB054, administered as intravenous (IV) infusion, in Japanese participants with Parkinson's disease (PD). The secondary objectives are to evaluate the immunogenicity, and serum pharmacokinetics (PK) profile of BIIB054 after single and multiple dose administration.

Description

 

Details
Condition Parkinson's disease
Treatment Placebo, BIIB054
Clinical Study IdentifierNCT03716570
SponsorBiogen
Last Modified on3 April 2020

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note